Abstracts tagged "quality improvement"

Abstract Number: 1202 • 2019 ACR/ARP Annual Meeting
Testing Rheumatoid Arthritis Performance Measures to Optimize Treat to Target Strategies
Claire Barber¹, Dianne Mosher ², Glen Hazlewood ¹, Paul MacMullan ², Cheryl Barnabe ², Victoria Bohm ², James Rankin ², Joanne Homik ³, Kelly English ⁴, Karen Tsui ⁵, Bo Pan ⁶, Martina Stevenson ², Namneet Sandhu ², Andrea Emrick ², Liam Martin ¹, Caylib Durand ², Michelle Jung ² and Diane Lacaille ⁷, ¹University of Calgary, Calgary, Canada, ²University of Calgary, Calgary, AB, Canada, ³University of Alberta, Edmonton, Canada, ⁴Arthritis Patient Advocacy Board, Vancouver, BC, Canada, ⁵Arthritis Patient Advisory Board, Toronto, ON, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The purpose of this study was to operationalize and report on 3 Rheumatoid Arthritis (RA) performance measures previously identified in the Patient-Centered Framework for…
Abstract Number: 1210 • 2019 ACR/ARP Annual Meeting
Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity
Arash Hassantoufighi ¹, Rachel Lu-Do¹, Mamta Sherchan ¹, Christopher Collins ¹, Joshpaul Dhillon ² and Florina Constantinescu ¹, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²MedStar Washington Hospital Center, Department of Internal Medicine, Washington, DC
Background/Purpose: Giant Cell Arteritis (GCA) is an autoimmune vasculitis, most common in older adults with a peak incidence in the seventh decade. The diagnosis is…
Abstract Number: 255 • 2019 ACR/ARP Annual Meeting
Designing and Testing Treat to Target as a New Care Model in JIA Across a Network of Pediatric Rheumatology Centers
Esi Morgan¹, Janalee Taylor ², Tingting Qiu ³, Nancy Griffin ², Anne Paul ², Catherine Bingham ⁴, Danielle Bullock ⁵, Kerry Ferraro ⁶, Y Goh ⁷, Mileka Gilbert ⁸, Olha Halyabar ⁹, Karla Jones ¹⁰, Melanie Kohlheim ¹¹, Daniel J. Lovell ¹², Darby MacDonald ¹⁰, Emily Smitherman ¹³, Anjie Vago ¹⁴, Jennifer Weiss ¹⁵, Cagri Yildirim-Toruner ¹⁰, Angela Young ¹⁶, Michelle Batthish ¹⁷, Beth Gottlieb ¹⁸, Julia Harris ¹⁹, Melissa Hazen ²⁰, Ronald Laxer ⁷, Tzielan Lee ²¹, Melissa Mannion ²², Judyann Olson ²³, MIchael Shishov ²⁴, Sheetal Vora ²⁵ and Jonathan Burnham ²⁶, ¹Cincinnati Children’s Hospital, University of Cincinnati, Cinncinati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Penn State Hershey Children's, Hershey, ⁵University of Minnesota, Minneapolis, MN, ⁶PR-CON Parent Working Group, Fort Washington, PA, ⁷Hospital for Sick Children, Toronto, ON, Canada, ⁸Medical Univeristy of South Carolina, Charleston, SC, ⁹Boston Children's Hospital, Boston, ¹⁰Nationwide Children's Hospital, Columbus, OH, ¹¹PR-COIN Parent Working Group, Columbus, OH, ¹²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴PR-COIN Parent Working Group, Hershey, PA, ¹⁵Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁶PR-COIN Parent Working Group, Lexington, KY, ¹⁷McMaster University, Hamilton, Canada, ¹⁸Cohen Children's Hospital, New Hyde Park, NY, ¹⁹Children's Mercy Hospital, Kansas City, MO, ²⁰Boston Children's Hospital, Boston, MA, ²¹Stanford University School of Medicine, Palo Alto, ²²Children's of Alabama, Birmingham, ²³Medical College of WIsconsin, Milwaukee, WI, ²⁴Phoenix Children's, Phoenix, AZ, ²⁵Levine Children's, Charlotte, NC, ²⁶The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: In 2018 an international task force published a recommended Treat to Target (T2T) approach to juvenile idiopathic arthritis (JIA) treatment. In February 2019, 17…
Abstract Number: 1213 • 2019 ACR/ARP Annual Meeting
A Retrospective Review and Prospective Intervention for Outpatient Follow-Up of Hospitalized Patients in Rheumatology
Shakaib Hayat¹ and Stanley Ballou ², ¹Case Western Reserve University (MetroHealth), Cleveland, OH, ²Metrohealth medical center, Cleveland, OH
Background/Purpose: There is lack of appropriate outpatient follow-up (F/U) for hospitalized rheumatology patients, which can result in disease recurrence and recurrent inpatient admissions1. This is…
Abstract Number: 304 • 2019 ACR/ARP Annual Meeting
The ACR’s Rheumatology Informatics System for Effectiveness (RISE) Demonstrates Improvements in Many Measures of Quality of Care Between 2015 and 2017
Zara Izadi¹, Gabriela Schmajuk ², Julia Kay ³, Michael Evans ¹ and Jinoos Yazdany ³, ¹UCSF Division of Rheumatology, San Francisco, ²UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: The ACR’s Rheumatology Informatics System for Effectiveness (RISE) is an EHR‐enabled registry that represents over 36% of the U.S. clinical rheumatology workforce and calculates…
Abstract Number: 1862 • 2019 ACR/ARP Annual Meeting
Treat to Target Opportunities – Design, Testing, and Adoption of a Novel EHR-Integrated Electronic System to Engage Rheumatologists and Capture Decision Making
Eric Newman¹, Jonida Cote ¹ and Joseph Chronowski ¹, ¹Geisinger, Danville, PA
Background/Purpose: Treat to Target (T2T) opportunities and rheumatologist decision making are not defined, captured, or reportable within existing electronic health record (EHR) software. We developed…
Abstract Number: 311 • 2019 ACR/ARP Annual Meeting
Documenting Bone Health for Veterans with Rheumatoid Arthritis in an Outpatient Academic Clinic: A Multiphase Quality Improvement Project
Melissa DeFoe¹, Rabih Nayfe ², Una Makris ³, Rashmi Arora ³ and Swathi Reddy ³, ¹VA North Texas Health Care System, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³University of Texas Southwestern Medical Center and the VA North Texas Health Care System, Dallas, TX
Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk of osteopenia and osteoporosis, which may result in fragility fractures and significant cost and morbidity. …
Abstract Number: 1863 • 2019 ACR/ARP Annual Meeting
Improving Pneumococcal Vaccination Rates in High Risk Rheumatology Patients
Heena Sheth¹, Grimes Vera ², Diana Rudge ², Gary Fischer ², Larry W. Moreland ¹ and Rohit Aggarwal ³, ¹University of Pittsburgh, Pittsburgh, PA, ²UPMC, Pittsburgh, ³University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: To improve Pneumococcal Vaccination rates in high risk Rheumatology patients on immunosuppressive therapy.Methods: The study was a quality improvement project based on the pre-post-intervention…
Abstract Number: 317 • 2019 ACR/ARP Annual Meeting
Improving Adherence to Pregnancy Screening in Patients on Teratogenic Medications Using an Electronic Medical Record Alert System: A Quality Improvement Initiative
Vy Do¹, MaiLan Nguyen ¹, Keiji Akamine ², Julie Fuller ¹, Lorien Nassi ¹, Tracey Wright ³ and Katie Stewart ¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Tokyo Metropolitan Children's Medical Center, Tokyo, Japan, ³University of Texas Southwestern, Texas Scottish Rite Hospital for Children, Children's Health, Dallas, TX
Background/Purpose: Mycophenolate is widely prescribed in the rheumatology setting. However, usage of mycophenolate during the first trimester of pregnancy is associated with an increased risk…
Abstract Number: 1865 • 2019 ACR/ARP Annual Meeting
Improving Lupus Care Index Documentation in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Fatima Barbar-Smiley¹, Stephanie Lemle ¹, Cagri Yildirim-Toruner ¹, Edward Oberle ¹, Darby McDonald ¹, Vidya Sivaraman ² and Stacy Ardoin ¹, ¹Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital and The Ohio State University, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) affects both adults and children with an estimated prevalence in children of 8/100,000. More than 1000 deaths related to SLE…
Abstract Number: 318 • 2019 ACR/ARP Annual Meeting
Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic
Francine Castillo¹, Michael Dodge ¹, Jung Hee Noh ², Laura Trupin ¹, Jinoos Yazdany ³ and Sarah Goglin ³, ¹University of California, San Francisco, San Francisco, CA, ²Zuckerberg San Francisco General Hospital, San Francisco, CA, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Hydroxychloroquine (HCQ) prescribing is standard of care for patients with SLE. The main potential side effect is retinal toxicity, especially at higher doses and…
Abstract Number: 2579 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity
Eric Liu¹ and Andras Perl ², ¹SUNY Upstate University Medical Center, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in our field of work with retinal toxicity being a known possible long-term side effect of the…
Abstract Number: 319 • 2019 ACR/ARP Annual Meeting
A Pragmatic Randomized Trial to Improve Safe Dosing of Hydroxychloroquine
Milena Gianfrancesco¹, Sara Murray ¹, Michael Evans ², Gabriela Schmajuk ³ and Jinoos Yazdany ⁴, ¹University of California, San Francisco, San Francisco, ²University of California San Francisco, San Francisco, ³UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ⁴UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Although generally well tolerated, the long-term use of hydroxychloroquine (HCQ) may lead to irreversible and potentially vision-threatening retinal toxicity. The American Academy of Ophthalmology…
Abstract Number: 320 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution
Rebecca Overbury¹, Jakrapun Pupaibool ², Christopher Hansen ³, Daniel Clegg ⁴ and Dorota Lebiedz-Odrobina ⁵, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah, Division of Infectious Diseases, Salt Lake City, UT, ³University of Utah, Department of Dermatology, Salt Lake City, UT, ⁴University of Utah, Salt Lake City, UT, ⁵University of Utah, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Research has shown potential retinal toxicity rates from HCQ as high as 7.5%. Research suggests toxicity is dose-related. In 2016, the American Academy of…
Abstract Number: 321 • 2019 ACR/ARP Annual Meeting
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Tara Skorupa¹ and Robert Shmerling ¹, ¹Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.